首页 | 本学科首页   官方微博 | 高级检索  
     


Integrin‐Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation
Authors:Nick Cox  James R. Kintzing  Mark Smith  Gerald A. Grant  Prof. Jennifer R. Cochran
Affiliation:1. Stanford ChEM-H Medicinal Chemistry Knowledge Center, Stanford University, Stanford, CA, USA;2. Department of Bioengineering, Stanford University, Stanford, CA, USA;3. Department of Neurosurgery, Stanford University, Stanford, CA, USA
Abstract:Antibody–drug conjugates (ADCs) offer increased efficacy and reduced toxicity compared to systemic chemotherapy. Less attention has been paid to peptide–drug delivery, which has the potential for increased tumor penetration and facile synthesis. We report a knottin peptide–drug conjugate (KDC) and demonstrate that it can selectively deliver gemcitabine to malignant cells expressing tumor‐associated integrins. This KDC binds to tumor cells with low‐nanomolar affinity, is internalized by an integrin‐mediated process, releases its payload intracellularly, and is a highly potent inhibitor of brain, breast, ovarian, and pancreatic cancer cell lines. Notably, these features enable this KDC to bypass a gemcitabine‐resistance mechanism found in pancreatic cancer cells. This work expands the therapeutic relevance of knottin peptides to include targeted drug delivery, and further motivates efforts to expand the drug‐conjugate toolkit to include non‐antibody protein scaffolds.
Keywords:antitumor agents  drug delivery  integrins  knottins  peptides
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号